Stockscreener 앱 받기
0.2417
3.24%
-0.0081
시간 외 거래:
.22
-0.0217
-8.98%
전일 마감가:
$0.2498
열려 있는:
$0.254
하루 거래량:
32.92M
Relative Volume:
10.08
시가총액:
$15.00M
수익:
$69.49M
순이익/손실:
$-21.13M
주가수익비율:
-0.3724
EPS:
-0.649
순현금흐름:
$-14.46M
1주 성능:
+5.96%
1개월 성능:
-19.86%
6개월 성능:
-52.13%
1년 성능:
-42.45%
1일 변동 폭
$0.228
$0.2755
1주일 범위
$0.1927
$0.2791
52주 변동 폭
$0.1927
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
명칭
Cosmos Health Inc
전화
312-536-3102
주소
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.2417 | 14.72M | 69.49M | -21.13M | -14.46M | -0.649 |
MCK
Mckesson Corp
|
779.80 | 91.29B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
277.09 | 54.76B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
226.28 | 53.02B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
79.97 | 9.24B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.23 | 993.78M | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc 주식(COSM)의 최신 뉴스
Cosmos Health Introduces Four 18 Series Products with Projected Annualized Revenue and Gross Profit in the United States - marketscreener.com
Cosmos Health projects $22.7M revenue from U.S. product line - Investing.com
Cosmos Health Provides Update on United States Portfolio; - GlobeNewswire
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit - marketscreener.com
Science-driven 18 Series aims for $17M profit in U.S. launch - Stock Titan
$Cosmos Health (COSM.US)$ just waiting to see better volume - Moomoo
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Cosmos Health (COSM) Secures New Contract Manufacturing Orders - GuruFocus
Cosmos Health Gets New Contract Manufacturing Orders for 253,657 Units Across Multiple Medicines - marketscreener.com
Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines - GlobeNewswire
Cosmos Health Stock (COSM) Opinions on EU Expansion and Antiseptic Sales Growth - Quiver Quantitative
Cosmos Health (NASDAQ: COSM) CEO swaps $45K company debt for shares - Stock Titan
Cosmos Health sets three-year targets for antiseptic brands By Investing.com - Investing.com Australia
Cosmos Health sets three-year targets for antiseptic brands - Investing.com
C-Scrub antiseptic tops $1.5M, aims for $7.4M across Europe - Stock Titan
Cosmos Health (NASDAQ: COSM) CEO gets 701K shares for $160K debt - Stock Titan
Cosmos Health Signs Letter of Intent to Buy Doc Pharma - Moomoo
Cosmos Health (COSM) Plans Acquisition of Doc Pharma - GuruFocus
Cosmos Health director awarded 20,000 shares | COSM Insider Trading - Stock Titan
Cosmos Health (NASDAQ: COSM) director receives 20,000-share equity award via RSU conversion - Stock Titan
Cosmos Health (NASDAQ: COSM) awards Demetriades 20K shares, now holding 55K - Stock Titan
Director at Cosmos Health (NASDAQ: COSM) awarded 40,000 shares - Stock Titan
Cosmos Health (COSM) grants 20,000 shares of stock to director - Stock Titan
Cosmos Health (NASDAQ: COSM) CFO receives 850K-share equity award via RSU conversion - Stock Titan
Cosmos Health (COSM) CEO awarded 2.35M shares via RSU conversion - Stock Titan
Cosmos Health Inc. Announces Proposed Acquisition of Doc Pharma S.A. to Enhance Vertical Integration and Product Portfolio - Quiver Quantitative
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio - The Manila Times
Cosmos Health pursues Doc Pharma deal, adding $6.7M in sales - Stock Titan
Cosmos Health Secures Additional 180-Day Nasdaq Extension To Regain Bid Price Compliance - TradingView
Cosmos Health gets Nasdaq extension to regain $1 minimum bid price - Investing.com
Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance - The Manila Times
Cosmos Health gets Dec. 7 deadline from Nasdaq; reverse split only last resort - Stock Titan
Cosmos Health (COSM) Secures Manufacturing Deal with Verisfield S.A. - GuruFocus
Cosmos Health CEO addresses shareholders amid stock decline - Investing.com UK
Cosmos Health targets $200M revenue by 2029, driven by U.S. expansion - scanx.trade
$20 Million in Liquid Assets Support Rapid Growth Including Acquisitions, Bio Pharma Production and Nanotechnology Initiatives for Diversified Global Heath Leader Cosmos Health, Inc. (Nasdaq: COSM) - Barchart.com
$20 Million in Liquid Assets Support Rapid Growth Including Acquisitions, Bio Pharma Production and Nanotechnology Initiatives for Diversified Global Heath Leader Cosmos Health, Inc. (Nasdaq: COSM) | FinancialContent - FinancialContent
Cosmos Health subsidiary secures manufacturing deal By Investing.com - Investing.com Australia
Cosmos Health subsidiary secures manufacturing deal - Investing.com
Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries - The Manila Times
Cosmos Health Inc. - Via Ritzau
Cosmos Health CEO addresses shareholders amid stock decline By Investing.com - Investing.com Nigeria
Cosmos Health CEO Issues Letter to Shareholders: Building - GlobeNewswire
Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare PlatformRecord Growth with U.S. Expansion Underway - The Manila Times
Cosmos Health subsidiary secures 5-year manufacturing deal - Investing.com UK
Cosmos Health (COSM) Launches New Capsule Production and Signs C - GuruFocus
Cosmos Health subsidiary secures 5-year manufacturing deal By Investing.com - Investing.com Canada
Cosmos Health Inc. Subsidiary Cana Laboratories Inaugurates New Capsule Production Line and Secures Contract with Provident Pharmaceuticals - Quiver Quantitative
Cosmos Health Inaugurates State-of-the-Art Capsule - GlobeNewswire
Cosmos Health Inaugurates State-of-the-Art Capsule Production Line With New 5-Year Contract Manufacturing Agreement With Provident Pharmaceuticals for 385,000 Units of CERTORUN - 富途牛牛
Cosmos Health (COSM) Expands Innovation with Patent Acquisition - GuruFocus
Cosmos Health Inc (COSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cosmos Health Inc 주식 (COSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Jun 10 '26 |
Buy |
0.23 |
701,447 |
160,000 |
13,263,361 |
| Siokas Grigorios | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.37 |
388,532 |
145,000 |
8,861,914 |
| Siokas Grigorios | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.41 |
291,262 |
120,000 |
8,473,382 |
| Siokas Grigorios | Chief Executive Officer |
Jan 23 '26 |
Buy |
0.50 |
90,325 |
45,000 |
8,182,120 |
| Siokas Grigorios | Chief Executive Officer |
Jan 20 '26 |
Buy |
0.50 |
353,321 |
175,000 |
8,091,795 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '26 |
Buy |
0.45 |
493,495 |
220,000 |
7,738,474 |
| Siokas Grigorios | Chief Executive Officer |
Jan 12 '26 |
Buy |
0.50 |
113,185 |
57,000 |
7,244,979 |
| Siokas Grigorios | Chief Executive Officer |
Jan 08 '26 |
Buy |
0.52 |
156,190 |
81,000 |
7,131,794 |
| Siokas Grigorios | Chief Executive Officer |
Jan 07 '26 |
Buy |
0.52 |
124,880 |
65,000 |
6,975,604 |
| Siokas Grigorios | Chief Executive Officer |
Jan 06 '26 |
Buy |
0.54 |
133,953 |
72,000 |
6,850,724 |
11.43%
3.16%
자본화:
|
볼륨(24시간):